A myriad of imaging techniques and targets have been tested to identify high-risk plaques and ultimately improve patient cardiovascular risk-stratification [1]. In this issue of Atherosclerosis, Khare et al. examine the urokinase-type plasminogen activator receptor (uPAR) as a novel positron emission tomography (PET) imaging target in atherosclerosis [2]. The findings of this initial proof-of-concept study are intriguing: could targeting uPAR be a bullseye for PET imaging of atherosclerotic plaque inflammation?